相关实验视频

Updated: Mar 7, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

细菌系21 EGFR V831H突变突变在先进NSCLC对almonertinib的耐药性:一个病例报告

Daxia Cai¹, Jian Lou¹, Yanyan Zhu²

¹Cancer Center, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Hospital of Zhejiang University, Lishui, China.

Frontiers in oncology

|March 6, 2026

概括

肺癌中的生殖系EGFR V831H突变很少见,可能导致对EGFR氨酸激酶抑制剂 (TKI) 的初级耐药性. 这一案例凸显了用这种特定EGFR突变治疗非小细胞肺癌的挑战.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

细菌系表皮生长因子受体 (EGFR) 突变在癌症中不常见,对它们对氨酸激酶抑制剂 (TKI) 反应的影响的理解有限.
EGFR V831H变异异常见,表现出构成性活性,但缺乏足够的治疗敏感性数据.

研究的目的:

报告一个先进的非小细胞肺癌 (NSCLC) 病例,该病例具有生殖系EGFR V831H突变.
研究这种罕见突变对EGFR-TKI治疗的临床意义和治疗反应.

主要方法:

一名患有IIIB期肺腺癌的患者接受了成像,组织病理学和全面的基因组分析.
EGFR V831H突变的生殖系起源在患者和家庭样本上使用桑格测序得到证实.
治疗包括抗结核疗法,其次是第三代EGFR-TKI的almonertinib.

主要成果:

这位患者同时出现了KRAS G12V突变和潜伏的结核病感染.
尽管接受了阿尔蒙尼蒂尼布治疗,疾病进展迅速 (20天内),表明原发性耐药性.
患者出现了新的大脑转移,并在治疗开始后一个月死亡.

结论:

这种病例表明NSCLC中对almonertinib的初级耐药性,具有生殖系EGFR V831H突变.
变种V831H可能会产生固有的TKI耐药性,可能受到同时发生的KRAS突变和药物相互作用的影响.
进一步的研究对于开发针对NSCLC罕见的生殖系EGFR突变的有效策略至关重要.

关键词:

欧洲农业基金 V831H 在NSCLCLC中,我们可以看到NSCLCLC.阿尔蒙尔蒂尼布 (almonertinib) 是一种药物.案例报告案例报告电阻的阻力可以

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...